Last presentation, Cepheid talked about: what is Honeycomb?
Strong Progress on High Multiplex Honeycomb
Completed Prototype on Honeycomb
Completed Prototype PCR Reaction
Fluidic Feasibility Achieved
Targeted release in 2015
Microwells, Honeycomb, Prototype, What is this stuff and what does it mean to us CPHD Investors and our place in the marketplace
Story this AM mentioned Nigeria as next nation in line to acquire Ebola. Nigeria major oil producer. Some how some way I think CPHD will fit in this equation. The oil companies will not use second rate company with no track record. So, if it happens, Cepheid, remember this is OIL $ even though it is in Africa?
I hope CPHD was smart enough to add a clause about those cheap GX for TB only.!!!!!!!
In the Nasdaq chart of short sales, it whows 23 days to cover, but this is November data. I don't know how much to hang my hat on a number that old. Do you have any newer number of shares having short interest. Would really like to hear a number from late Jan or Feb.
06 do you have any newer short interest figures. I also thought the shares outstanding was 61K shares. This would really make the short interest a very high percentage of total shares.
Cepheid (NASDAQ:CPHD) reported gains in early morning session on Tuesday and has advanced further in the past few minutes on superior volume. The stock is now higher 1.41 at $55.00. Cepheid has surged past the upper end of a 3-week trading range on Tuesday morning and has made a new high for the year.
Hunter. I was almost in panic mode this AM, when I sold ALL of my Cepheid holdings. I have been a big time holder since 2000. Was carrying an average of 30,000 though most of those years. I rode it down in 2008, Borrowed some money from my CD and then watched it climb back from the depth of $4.00 until today. When you are that invested you better not make any mistakes. The biggest threat currently, is an eathquake that could knock out the company to some (I think great extent, at least for a while..
So feeling naked, I went out any bought some large quantities of call and put options. Learned about the value of options from Rick, this board, who used to post about the effectiveness. Options have become a big part of what I trade with Cepheid.
View the Hologic Q report. Revenue down. . . . not for CPHD, though.
A Whole New Opportunity For Hologic Inc?
by Stephen D., Simpson,, The Motley Fool Feb 24th 2014 6:30PM
Updated Feb 24th 2014 6:32PM
Women's health specialist Hologic has had a rough go of it. At a time when most companies in the medical equipment or diagnostics markets can look back on a great two-year run in their share prices, Hologic's shares have chopped around and gone nowhere fast (up just 2%). This isn't a mistake on the part of the market, as Hologic has underperformed due to slow adoption of 3D tomosynthesis, changing recommendations for cervical cytology testing, and fiercer competition in diagnostics.
In hiring former Stryker CEO Stephen MacMillan, though, the board may have put this company back on the right track. MacMillan's experience in improving sales efforts and integrating acquisitions both speak to areas where Hologic needs to improve, and there is certainly room for improvement here.
Diagnostics not getting any easier
As the company's fiscal first quarter results (released earlier this month) show, Hologic has to get its diagnostics business turned around and growing again. Revenue fell more than 10% at a time when other diagnostic companies, including Abbott Labs, Becton Dickinson , and Cepheid , are doing notably better.
Cepheid highlighted its continued leadership in cervical cytology in a recent presentation to lenders, but the reality is that ThinPrep was still down 11% in the quarter as the market continues to adapt to new recommendations about screening intervals. At the same time, the company's market-leading blood screening business saw a 14% decline in revenue.
There are still valuable parts with which Hologic can work. The molecular diagnostics business was up 3% this quarter and helped by Aptima, Hologic has been gaining on Qiagen in HPV testing. What's more, the company has a large menu of tests across multiple treatment areas.
they spent nearly a third to a half billion dollars. They bought the French RNA company Actigenics.
Cepheid Quietly Acquires microRNA Company Actigenics ...
August 09, 2006
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Cepheid today acquired Actigenics for an undisclosed sum, the company said today.
Cepheid acquired the French company for its microRNA portfolio. Actigenics possesses both therapeutic and diagnostic rights to validated microRNAs. Cepheid plans to out-license therapeutic applications of these microRNAs, the company said in a statement.
The microRNAs may potentially provide the basis for a broad range of proprietary markers for Cepheid in “cancerspecific markers, infection-specific markers, inflammation-specific markers, and surrogate markers of complex regulatory mechanisms,” the company said.
Stock analysts at Cowen and Company increased their price objective on shares of Cepheid (NASDAQ:CPHD) from $52.00 to $53.00 in a report issued on Friday, StockRatingsNetwork reports. Cowen and Company’s price target would indicate a potential upside of 6.26% from the company’s current price.
Research analysts at Canaccord Genuity boosted their price target on shares of Cepheid (NASDAQ:CPHD) from $50.00 to $55.00 in a report released on Friday, Stock Ratings Network.com reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price target points to a potential upside of 10.26% from the stock’s previous close.
I tried to post this message about Cepheid Bonds a couple days ago. Instead of showing the above article about a Cepheid Bond sale(s), the Cepheid message board posted something about "can this continue?.
So I'm really confused about the meaning of the sale of bonds. Can anyone shed any light?
Also, I am pasting a couple references, from the "Bond" post, that I think might be key in understanding the transaction. I have no idea how the bonds will affect the price of shards. Maybe the answer to a couple of questions below will clarify the meaning of the Bond traction.
First: The size of the offering was increased from the previously announced aggregate principal amount of $250 million.
2nd: sale is expected to close on February 10, 2014
3rd: The notes will have an initial conversion rate of 15.3616 shares of Cepheid common stock per $1,000 principal amount of notes (which is subject to adjustment in certain circumstances). This represents an initial effective conversion price of approximately $65.10 per share. The initial conversion price represents a premium of approximately 32.5% to the $49.13 per share closing price of Cepheid common stock on February 4, 2014." Could there be any connection between the Mizuho target price of $65?
4th: Cepheid common stock concurrently with, or shortly after, the pricing of the notes. These activities could have the effect of increasing or reducing the size of any decline in the price of Cepheid common stock concurrently with, or shortly after, the pricing of the notes
5th: Upon conversion, the notes may be settled in shares of Cepheid common stock, cash or a combination of cash and shares of Cepheid common stock, at Cepheid's election.
Feb 4, 2014
« Previous Release PDF Add to Briefcase File is in Briefcase
Cepheid Prices $300 Million Convertible Senior Notes due 2021
SUNNYVALE, Calif., Feb. 4, 2014 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced that it has priced $300 million aggregate principal amount of 1.25% Convertible Senior Notes due 2021 (the "notes"). The size of the offering was increased from the previously announced aggregate principal amount of $250 million. The notes will be sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Cepheid also granted the initial purchasers of the notes an option to purchase up to an additional $45 million aggregate principal amount of the notes, solely to cover over-allotments. The sale is expected to close on February 10, 2014, subject to customary closing conditions. Morgan Stanley & Co. LLC and Jefferies LLC are acting as initial purchasers of the notes.
Prior to the close of business on the business day immediately preceding August 1, 2020, the notes will be convertible at the option of holders during certain periods, upon satisfaction of certain conditions. Thereafter, the notes will be convertible at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Upon conversion, the notes may be settled in shares of Cepheid common stock, cash or a combination of cash and shares of Cepheid common stock, at Cepheid's election.
The notes will have an initial conversion rate of 15.3616 shares of Cepheid common stock per $1,000 principal amount of notes (which is subject to adjustment in certain circumstances). This represents an initial effective conversion price of approximately $65.10 per share. The initial conversion price represents a premium of approximately 32.5% to the $49.13 per share closing price of Cepheid common stock on February 4, 2014.
The notes will be unsecured, senior obligations of Cepheid, and interest will be payable semi-annually in cash at a rate of 1.25% per annum on each on February 1 and August 1, beginning on August 1, 2014. The notes will mature on February 1, 2021, unless repurchased or converted in accordance with their terms prior to such date. Cepheid may not redeem the notes prior to their maturity.
In connection with the pricing of the notes, Cepheid has entered into capped call transactions with one or more of the initial purchasers of the notes or their respective affiliates and one or more other financial institutions (the "counterparties"). The capped call transactions are expected generally to reduce the potential dilution and/or offset the cash payments that Cepheid could be required to make in excess of the principal amount upon conversion of the notes.
In connection with establishing their initial hedge of the capped call transactions, the counterparties and/or their respective affiliates may enter into various derivative transactions with respect to the Cepheid common stock and/or purchase Cepheid common stock concurrently with, or shortly after, the pricing of the notes. These activities could have the effect of increasing or reducing the size of any decline in the price of Cepheid common stock concurrently with, or shortly after, the pricing of the notes. In addition, the counterparties and/or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Cepheid common stock and/or purchasing or selling Cepheid common stock or other securities of Cepheid in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so during any observation period related to a conversion of notes or following any repurchase of notes by Cepheid on any fundamental change repurchase date or otherwise). This activity could also cause or avoid an increase or a decrease in the market price of Cepheid common stock or the notes.
Cepheid estimates that the net proceeds from the offering will be approximately $291.9 million (or approximately $335.8 million if the initial purchasers exercise their over-allotment option in full) after deducting the estimated initial purchasers' discounts and estimated offering expenses payable by Cepheid. Cepheid intends to use $21.8 million of the net proceeds to pay the cost of the capped call transactions. Cepheid expects to use the remainder of the net proceeds from the offering of the notes for general corporate purposes, including potential acquisitions and strategic transactions. If the initial purchasers exercise their over-allotment option, Cepheid intends to use the resulting additional net proceeds of the sale of the additional notes to pay the cost of entering into additional capped call transactions with the counterparties and for general corporate purposes, including potential acquisitions and strategic transactions.
This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities (including the shares of Cepheid common stock, if any, into which the notes are convertible) and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. Any offers of the notes will be made only by means of a private offering memorandum.
The notes and any shares of common stock issuable upon conversion of the notes have not been registered under the Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.
Cepheid (CPHD) Shares March Higher, Can It Continue?
February 03, 2014
by Zacks Equity Research Published on February 03, 2014 | No Comments
As of late, it has definitely been a great time to be an investor in Cepheid Inc. (CPHD - Analyst Report). The stock has moved higher by 15.3% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.
We certainly think that this might be the case, particularly if you consider CPHD’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as CPHD has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company.
Cepheid logo Analysts at Jefferies Group increased their price objective on shares of Cepheid
(NASDAQ:CPHD) from $36.00 to $43.00 in a research report issued to clients and investors on Friday, American Banking News reports. Jefferies Group’s price objective would suggest a potential downside of 18.65% from the company’s current price.
Cepheid (NASDAQ:CPHD) last announced its earnings results on Friday, January 31st. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.04. The company had revenue of $113.30 million for the quarter, compared to the consensus estimate of $102.17 million.
CPHD has been the subject of a number of other recent research reports. Analysts at Raymond James raised their price target on shares of Cepheid from $50.00 to $57.00 in a research note to investors on Friday. Separately, analysts at Oppenheimer raised their price target on shares of Cepheid from $43.00 to $54.00 in a research note to investors on Friday. Finally, analysts at UBS AG raised their price target on shares of Cepheid from $48.00 to $55.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $48.25.
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.
Does anybody get this report? Maybe just to get a couple key paragraphs from that report as to why not higher?
Also, if anybody would have shorted any time in the last month, they have to have their head examined. Also, must have balls of steel.
hey 06 can you direct me to the stocks info sheet. I don't know, for some reason this AM, I'm feeling good and frankly a little lazy.